Plaintiffs who won $9 billion in punitive damages in the first federal bellwether trial over diabetes drug Actos said the verdict should be upheld because there is no bright-line rule that punitive damages have to be in a single-digit ratio with compensatory damages.
Co-lead counsel Richard J. Arsenault, of Neblett, Beard & Arsenault of Alexandria, La., and Paul J. Pennock, of Weitz & Luxenberg in New York wrote—in their memorandum in opposition to defendants’ motion for a new trial—that deterrence of future bad behavior should warrant upholding the award.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
